News

Nova Mentis Autism Clinical Study Approved by Institutional Review Board

Vancouver, British Columbia – February 25, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a leader in the development of psilocybin and other psychedelic compounds with broad cognitive, behavioral, and peripheral physiologic effects, has received approval for its first clinical program in Autism Spectrum Disorder (ASD). The Company has
Read More »

Nova Mentis Expands Pre-Clinical Development Pipeline

Company Begins Fragile X Syndrome Treatment with its Proprietary Psilocybin Drug Vancouver, British Columbia – February 18 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: LIBFF) (“NOVA” or the “Company”), a leader in the development of serotonergic psychedelic compounds, is pleased to announce that the Company is expanding its pre-clinical program to develop
Read More »

Nova Mentis Appoints Gary R. Harlem to Scientific Advisory Board

Vancouver, British Columbia – February 11, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) (“NOVA” or the “Company”), a leader in the development of serotonergic psychedelic compounds, is pleased to announce that it has appointed Gary R. Harlem to its Scientific Advisory Board, effective immediately. Mr. Harlem is the founder and CEO of
Read More »

Nova Launches Preclinical Autism Spectrum Disorder Therapeutic Study Develops Microbiome Diagnostic Index

Vancouver, British Columbia – January 26, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) (“NOVA” or the “Company”) is pleased to announce that it has commenced the diagnostic and treatment phase of its ongoing preclinical model study of autism spectrum disorder (ASD).   In this model, which is well accepted by neuroscientists, pregnant rats
Read More »

Nova Mentis to be Listed in the First-Ever Psychedelic Index

Vancouver, British Columbia – January 25, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) (“NOVA” or the “Company”) is pleased to announce that it has been included in the world’s first North American Psychedelic Index. Based on this index, The Horizon Psychedelic Stock Index ETF is expected to commence trading Jan. 27, 2021
Read More »